Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Aspirin for primary prevention of cardiovascular disease in women.

Jneid H.

Methodist Debakey Cardiovasc J. 2010 Nov-2011 Jan;6(4):37-42. Review.

PMID:
21088658
[PubMed - indexed for MEDLINE]
2.

Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.

Wolff T, Miller T, Ko S.

Ann Intern Med. 2009 Mar 17;150(6):405-10. Review.

PMID:
19293073
[PubMed - indexed for MEDLINE]
3.

Where do we currently stand with advice on hormone replacement therapy for women?

Bozkurt B.

Methodist Debakey Cardiovasc J. 2010 Nov-2011 Jan;6(4):21-5. Review.

PMID:
21088655
[PubMed - indexed for MEDLINE]
4.

Aspirin in primary prevention: USPSTF recommendations.

Aalbers J.

Cardiovasc J Afr. 2010 May-Jun;21(3):176. No abstract available.

PMID:
20532445
[PubMed - indexed for MEDLINE]
Free Article
5.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

PMID:
12512736
[PubMed - indexed for MEDLINE]
Free Article
6.

Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.

Morimoto T, Fukui T, Lee TH, Matsui K.

Am J Med. 2004 Oct 1;117(7):459-68. Review.

PMID:
15464702
[PubMed - indexed for MEDLINE]
7.

Aspirin for primary prevention of cardiovascular disease events.

Nemerovski CW, Salinitri FD, Morbitzer KA, Moser LR.

Pharmacotherapy. 2012 Nov;32(11):1020-35. doi: 10.1002/phar.1127. Epub 2012 Sep 27. Review.

PMID:
23019080
[PubMed - indexed for MEDLINE]
8.

Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.

Butalia S, Leung AA, Ghali WA, Rabi DM.

Cardiovasc Diabetol. 2011 Apr 1;10:25. doi: 10.1186/1475-2840-10-25. Review.

PMID:
21453547
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Aspirin for primary prevention: yes or no?

Selak V, Elley CR, Wells S, Rodgers A, Sharpe N.

J Prim Health Care. 2010 Jun;2(2):92-9.

PMID:
20690297
[PubMed - indexed for MEDLINE]
10.

Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women.

Rivera CM, Song J, Copeland L, Buirge C, Ory M, McNeal CJ.

J Womens Health (Larchmt). 2012 Apr;21(4):379-87. doi: 10.1089/jwh.2011.2990. Epub 2012 Feb 3.

PMID:
22303820
[PubMed - indexed for MEDLINE]
11.

Representation of women in randomized clinical trials of cardiovascular disease prevention.

Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB, Newby LK.

Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):135-42. doi: 10.1161/CIRCOUTCOMES.110.868307. Epub 2010 Feb 16. Review.

PMID:
20160159
[PubMed - indexed for MEDLINE]
Free Article
12.

PRO: Should aspirin be used in all women older than 65 years to prevent stroke?

Hsia J.

Prev Cardiol. 2007 Fall;10 Suppl 4:6-11.

PMID:
17917525
[PubMed - indexed for MEDLINE]
13.

Aspirin use in the prevention of cardiovascular events.

Crutcher JM, Mallonee S, Daniels C.

J Okla State Med Assoc. 2007 Oct;100(10):383-7.

PMID:
18085095
[PubMed - indexed for MEDLINE]
14.

The female heart is vulnerable to cardiovascular disease: emerging prevention evidence for women must inform emerging prevention strategies for women.

Wenger NK.

Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):118-9. doi: 10.1161/CIRCOUTCOMES.110.942664. No abstract available.

PMID:
20233978
[PubMed - indexed for MEDLINE]
Free Article
15.

Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma.

Mallonee S, Daniels CG, Mold JW, Cline TL.

J Okla State Med Assoc. 2010 Jul;103(7):254-60.

PMID:
20821923
[PubMed - indexed for MEDLINE]
16.

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL.

JAMA. 2006 Jan 18;295(3):306-13. Erratum in: JAMA. 2006 May 3;295(17):2002.

PMID:
16418466
[PubMed - indexed for MEDLINE]
17.

AAA- a further step towards a moratorium for aspirin in the primary prevention.

Minar E.

Vasa. 2010 May;39(2):119-122. No abstract available.

PMID:
20521434
[PubMed - indexed for MEDLINE]
18.

Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.

Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF.

Clin Ther. 2012 Jun;34(6):1387-94. doi: 10.1016/j.clinthera.2012.04.004. Epub 2012 May 5.

PMID:
22560621
[PubMed - indexed for MEDLINE]
19.

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.

Lamotte M, Annemans L, Evers T, Kubin M.

Pharmacoeconomics. 2006;24(2):155-69.

PMID:
16460136
[PubMed - indexed for MEDLINE]
20.

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.

Greving JP, Buskens E, Koffijberg H, Algra A.

Circulation. 2008 Jun 3;117(22):2875-83. doi: 10.1161/CIRCULATIONAHA.107.735340. Epub 2008 May 27.

PMID:
18506010
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk